Maintenance: Wednesday, 22 November 2017, 07:00-08:00
Maintenance work on the ZORA servers is provided. There may be short interruptions in the service between 07:00 and 08:00. Thank you for your patience.
Martin-Killias, P; Stefan, N; Rothschild, S; Plückthun, A; Zangemeister-Wittke, U (2011). A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clinical Cancer Research, 17(1):100-110.
Huwiler, A; Bourquin, F; Kotelevets, N; Pastukhov, O; Capitani, G; Grütter, M G; Zangemeister-Wittke, U (2011). A prokaryotic S1P lyase degrades extracellular S1P in vitro and in vivo: Implication for treating hyperproliferative disorders. PLoS ONE, 6(8):e22436.
Stefan, N; Martin-Killias, P; Wyss-Stoeckle, S; Honegger, A; Zangemeister-Wittke, U; Plückthun, A (2011). DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. Journal of Molecular Biology, 413(4):826-43.
Marinov, M; Ziogas, A; Pardo, O E; Tan, L T; Dhillon, T; Mauri, F A; Lane, H A; Lemoine, N R; Zangemeister-Wittke, U; Seckl, M J; Arcaro, A (2009). AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clinical Cancer Research, 15(4):1277-1287.
Winkler, J; Martin-Killias, P; Plückthun, A; Zangemeister-Wittke, U (2009). EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Molecular Cancer Therapeutics, 8(9):2674-2683.
Belyanskaya, L L; Ziogas, A; Hopkins-Donaldson, S; Kurtz, S; Simon, H U; Stahel, R; Zangemeister-Wittke, U (2008). TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer, 60(3):355-365.